Archive: October 2023
Feature Article
Reappraisal of Cardiovascular Risk Factors in Patients With Chronic Myeloproliferative Neoplasms
Abstract: Cardiovascular (CV) risk factors are important contributors to thrombotic risk in the general population and in patients with chronic myeloproliferative neoplasms (MPNs). However, the role […]
Feature Article
The Use of Positron Emission Tomography Imaging to Guide Radiation Therapy
Abstract: Positron emission tomography (PET)-based biologic radiation planning has the potential to improve tumor control by improving the accuracy of radiation delivery, allow for rational adaptive […]
Letter From the Editor
Letter From the Editor: Doctors Without Boundaries
I was on vacation, it was 10 pm, and we were on our way home from dinner when I noticed that my cell phone had shut off. […]
Advances in Drug Development
The Impact of Financial Toxicity on Cancer Care
H&O What is financial toxicity, and how does it impact cancer therapy? JP Financial toxicity is a term used to describe the burdens, barriers, and distress […]
Prostate Cancer In Focus
Overcoming Immune Evasion in Advanced Prostate Cancer
H&O Why do some patients with prostate cancer respond to immune checkpoint inhibitors (ICIs), whereas others do not? AA Several clinical trials with ICIs, either alone […]
Advances in LLM
Mosunetuzumab, the First Bispecific Approved for Follicular Lymphoma
H&O What is mosunetuzumab (Lunsumio, Genentech) and how does it work? LEB Mosunetuzumab is a bispecific antibody-based T-cell engager with 2 binding sites. Unlike conventional monoclonal […]